Destination therapy with left ventricular assist devices: For whom and when?

Canadian Journal of Cardiology

Volumn 30, Issue 3, 2014, Pages 296-303

  Porepa, Liane F ^a   Starling, Randall C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; REGISTRIES; TREATMENT OUTCOME;

EID: 84894233191     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.12.017     Document Type: Review

References (35)

1. Writing Group Members, Lloyd-Jones D., Adams R.J., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. McMurray J.J., Petrie M.C., Murdoch D.R., Davie A.P. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998, 19(suppl P):P9-16.
3. Canadian Institute for Health Information. 2010; Table1A: Transplants, by Organ and Donor Type, Province of Treatment, Canada. Available at: . (Accessed August 16, 2013). http://www.cihi.ca/CIHI-ext-portal/pdf/internet/REPORT_STATS2010_PDF_EN.
4. Slaughter M.S., Rogers J.G., Milano C.A., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. NEngl J Med 2009, 361:2241-2251.
5. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209. [errata in 2011;123:e240 and 2011;124:e426].
6. Rogers J.G., Bostic R.R., Tong K.B., et al. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail 2012, 5:10-16.
7. Kirklin J.K., Naftel D.C., Kormos R.L., et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. JHeart Lung Transplant 2013, 32:141-156.
8. Baskett R., Crowell R., Freed D., et al. Canadian Cardiovascular Society focused position statement update on assessment of the cardiac patient for fitness to drive: fitness following left ventricular assist device implantation. Can J Cardiol 2012, 28:137-140.
9. Miller L.W., Guglin M. Patient selection for ventricular assist devices: a moving target. JAm Coll Cardiol 2013, 61:1209-1221.
10. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. NEngl J Med 2001, 345:1435-1443.
11. Stevenson L.W., Pagani F.D., Young J.B., et al. INTERMACS profiles of advanced heart failure: the current picture. JHeart Lung Transplant 2009, 28:535-541.
12. Starling R.C., Naka Y., Boyle A.J., et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). JAm Coll Cardiol 2011, 57:1890-1898.
13. Boyle A.J., Ascheim D.D., Russo M.J., et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. JHeart Lung Transplant 2011, 30:402-407.
14. ClinicalTrials.gov. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management (ROADMAP).Available at: . Accessed November 17, 2013. http://clinicaltrials.gov/show/NCT01452802.
15. ClinicalTrials.gov. The Evaluation of VAD InterVEntion Before Inotropic Therapy (REVIVE-IT). Available at: . Accessed November 17, 2013. http://clinicaltrials.gov/show/NCT01369407.
16. Fonarow G.C., Abraham W.T., Albert N.M., et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. JAm Coll Cardiol 2008, 52:190-199.
17. Nohria A., Hasselblad V., Stebbins A., et al. Cardiorenal interactions: insights from the ESCAPE trial. JAm Coll Cardiol 2008, 51:1268-1274.
18. Solomon S.D., Dobson J., Pocock S., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007, 116:1482-1487.
19. Szlachcic J., Massie B.M., Kramer B.L., Topic N., Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 1985, 55:1037-1042.
20. Weber K.T., Janicki J.S. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 1985, 55:22A-31A.
21. Mancini D.M., Eisen H., Kussmaul W., et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991, 83:778-786.
22. Gorodeski E.Z., Chu E.C., Reese J.R., et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail 2009, 2:320-324.
23. Sandner S.E., Wieselthaler G., Zuckermann A., et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation 2001, 104(12 Suppl 1):I171-I176.
24. Kim M.S., Kato T.S., Farr M., et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. JAm Coll Cardiol 2013, 61:2253-2261.
25. Flint K.M., Matlock D.D., Lindenfeld J., Allen L.A. Frailty and the selection of patients for destination therapy left ventricular assist device. Circ Heart Fail 2012, 5:286-293.
26. Cohn J.N., Johnson G., Ziesche S., et al. Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. NEngl J Med 1991, 325:303-310.
27. Kato T.S., Collado E., Khawaja T., et al. Value of peak exercise oxygen consumption combined with B-type natriuretic peptide levels for optimal timing of cardiac transplantation. Circ Heart Fail 2013, 6:6-14.
28. Smedira N., Hoercher K.J., Lima B., et al. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. JACC Heart Fail 2013, 1:31-39.
29. Starling R.C., Moazami N., Silvestry S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. NEngl J Med 2014, 370:33-40.
30. Sas G., Boothroyd L., Guertin J., et al. Evaluation of the evidence on the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage heart failure 2012, 1-7. Institut nationa d'excellence en snate et en services sociaux, Québec.
31. Alba A.C., Alba L.F., Delgado D.H., et al. Cost-effectiveness of ventricular assist device therapy as a bridge to transplantation compared with nonbridged cardiac recipients. Circulation 2013, 127:2424-2435.
32. Boothroyd L.J., Lambert L.J., Sas G., et al. Should eligibility for heart transplantation be a requirement for left ventricular assist device use? Recommendations based on a systematic review. Can J Cardiol 2013, 29:1712-1720.
33. Lietz K., Long J.W., Kfoury A.G., et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007, 116:497-505.
34. Teuteberg J.J., Ewald G.A., Adamson R.M., et al. Risk assessment for continuous flow left ventricular assist devices: does the destination therapy risk score work? An analysis of over 1,000 patients. JAm Coll Cardiol 2012, 60:44-51.
35. Cowger J., Sundareswaran K., Rogers J.G., et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. JAm Coll Cardiol 2013, 61:313-321.